Biotech Values

[poorgradstudent]

Respectifuy disagree but sipuleucel t and the new anti-pd1 antibodies counter the ipilimumab argument. trastuzumab and rituximab too.

I would separate the concept of eliciting a self-sustaining immune reaction versus self antigens with the concept of using antibodies to block receptors / ligand binding on cells. From a mechanistic perspective, I don't consider ipilimumab versus rituximab / herceptin to be in the same ___ ballpark. With apologies to Vincent Vega.